Free Trial
NASDAQ:ZBIO

Zenas Biopharma (ZBIO) Stock Price, News & Analysis

Zenas Biopharma logo
$11.56 -0.02 (-0.17%)
As of 05/1/2025 04:00 PM Eastern

About Zenas Biopharma Stock (NASDAQ:ZBIO)

Key Stats

Today's Range
$10.36
$11.72
50-Day Range
N/A
52-Week Range
$5.83
$26.25
Volume
193,471 shs
Average Volume
193,161 shs
Market Capitalization
$483.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00
Consensus Rating
Buy

Company Overview

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Receive ZBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zenas Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ZBIO Stock News Headlines

Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
See More Headlines

ZBIO Stock Analysis - Frequently Asked Questions

Zenas Biopharma's stock was trading at $7.90 at the start of the year. Since then, ZBIO stock has increased by 46.3% and is now trading at $11.56.
View the best growth stocks for 2025 here
.

Zenas Biopharma (ZBIO) raised $225 million in an initial public offering on Friday, September 13th 2024. The company issued 13,235,294 shares at a price of $17.00 per share.

Zenas Biopharma's lock-up period expired on Wednesday, March 12th. Zenas Biopharma had issued 13,235,294 shares in its initial public offering on September 13th. The total size of the offering was $224,999,998 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Top institutional investors of Zenas Biopharma include Alps Advisors Inc. (0.07%), Rhumbline Advisers (0.03%) and New York State Common Retirement Fund (0.01%).

Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas Biopharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZBIO
Previous Symbol
NASDAQ:ZBIO
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$45.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+246.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$483.20 million
Optionable
N/A
Beta
N/A
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:ZBIO) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners